Investor Relations

Overview

Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two product candidates that are in late stage development: lefamulin, potentially the first systemic pleuromutilin antibiotic for CABP and CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Thursday June 6, 2019 4:30 PM EDT
Jefferies 2019 Healthcare Conference

Wednesday May 15, 2019 4:20 PM EDT
Bank of America Merrill Lynch 2019 Health Care Conference

Wednesday May 1, 2019 8:00 AM EDT
Nabriva Therapeutics Corporate Update Call

SEC Filings

Filing date Description Form Filing Group View

An amendment to the SC 13G filing

SC 13G/A
3,4,5
View HTML

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

424B5
Registration Statements
View HTML

Investor Contacts

David Garrett
Vice President, Corporate Controller and Head of Investor Relations Nabriva Therapeutics plc
E-mail: david.garrett@nabriva.com